Seventeen years after the 2001 anthrax attacks, a pandemic—whether natural, accidental, or manmade—remains one of the greatest threats our nation faces. Congress enacted the Project BioShield Act in 2004 to facilitate the development of medical countermeasures by private manufacturers. Although significant progress has been made, gaps in preparedness remain. Join us on February 14 as we discuss the history of this critical program and release a new paper, Budgeting for Medical Countermeasures: An Ongoing Need for Preparedness, on options to ensure its sustainability.
This event is planned in accordance with congressional gift rules and government ethics.
Sen. Richard Burr (R-NC)
Chairman, Senate Select Committee on Intelligence
Sen. Tom Daschle
Former U.S. Senate Majority Leader
Rick Bright, Ph.D
Director, Biomedical Advanced Research and Development Authority (BARDA), U.S. Department of Health and Human Services
President and CEO, Bavarian Nordic
G. William Hoagland
Senior Vice President, BPC